Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial

Purpose. Proven efficacy of imatinib mesylate in gastrointestinal stromal tumour (GIST) has led to its use in advanced disease and, more recently, in adjuvant and neoadjuvant settings. The purpose of this study was to evaluate the optimal neoadjuvant imatinib duration to reduce the morbidity of surg...

Descripción completa

Detalles Bibliográficos
Autores principales: Doyon, C., Sidéris, L., Leblanc, G., Leclerc, Y. E., Boudreau, D., Dubé, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534224/
https://www.ncbi.nlm.nih.gov/pubmed/23316352
http://dx.doi.org/10.1155/2012/761576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534224/
https://www.ncbi.nlm.nih.gov/pubmed/23316352
http://dx.doi.org/10.1155/2012/761576

Ejemplares similares